The EGFR mutant NSCLC patients from whom models MGH707-1, MGH721-1, and MGH748-1 were derived progressed on first- and/or second-generation EGFR inhibitor regimens, including erlotinib, gefitinib, icotinib, and afatinib, alone and in combination with the anti-EGFR antibody cetuximab (Table 2). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.